

Revision date: 15-Aug-2016

Version: 2.2

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Ropivacaine Hydrochloride Solution for Injection

Trade Name:ROPIVACAINEChemical Family:Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Pharmaceutical product used as anesthetic agent

Details of the Supplier of the Safety Data Sheet Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Hazard Statements: Not Classified Not classified in accordance with international standards for workplace safety.

Pfizer Ltd

CT13 9NJ

Ramsgate Road

Sandwich, Kent

United Kingdom +00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Other Hazards	An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).
Note:	This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Material Name: Ropivacaine Hydrochloride Solution for Injection Revision date: 15-Aug-2016

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314) STOT SE 3 (H335)	**
SODIUM HYDROXIDE	1310-73-2	215-185-5	Skin Corr. 1A (H314)	**
Ropivacaine hydrochloride	132112-35-7	Not Listed	Acute 4; H302 Aquatic Acute 3; H402 Aquatic Chronic 3; H412	0.2

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*
SODIUM CHLORIDE	7647-14-5	231-598-3	Not Listed	*

Additional Information:

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. * Proprietary ** to adjust pH

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Most Important Symptoms and Effects, Both Acute and Delayed Symptoms and Effects of Exposure: Identification and/or Section 11 - Toxicological Information. Medical Conditions Aggravated by Exposure:	
Indication of the Immediate Medical Notes to Physician:	Attention and Special Treatment Needed None

5. FIRE FIGHTING MEASURES

Extinguishing Media:

Extinguish fires with CO2, extinguishing powder, foam, or water.

Version: 2.2

Material Name: Ropivacaine Hydrochloride Solution for Injection Revision date: 15-Aug-2016 Page 3 of 10

Version: 2.2

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Formation of toxic gases is possible during heating or fire. Products:

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize generating airborne mists and vapors. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:	Store as directed by product packaging.
Specific end use(s):	Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

HYDROCHLORIC ACID	
ACGIH Ceiling Threshold Limit:	2 ppm
Australia PEAK	5 ppm
	7.5 mg/m ³
Austria OEL - MAKs	5 ppm
	8 mg/m³
Belgium OEL - TWA	5 ppm
	8 mg/m³
Bulgaria OEL - TWA	5 ppm
	8.0 mg/m ³

Material Name: Ropivacaine Hydrochloride Solution for Injection Revision date: 15-Aug-2016

Page 4 of 10

Version: 2.2

Cyprus OEL - TWA	5 ppm
	8 mg/m ³
zech Republic OEL - TWA	8 mg/m ³
stonia OEL - TWA	5 ppm
	8 mg/m ³
Germany - TRGS 900 - TWAs	2 ppm
	3 mg/m ³
Germany (DFG) - MAK	2 ppm
	3.0 mg/m ³
Greece OEL - TWA	5 ppm
	7 mg/m ³
	8 mg/m ³
lungary OEL - TWA	-
reland OEL - TWAs	5 ppm 8 mg/m ³
	8 mg/m ³
aly OEL - TWA	5 ppm
	8 mg/m ³
apan - OELs - Ceilings	2 ppm
	3.0 mg/m ³
atvia OEL - TWA	5 ppm
	8 mg/m ³
ithuania OEL - TWA	5 ppm
	8 mg/m³
uxembourg OEL - TWA	5 ppm
	8 mg/m ³
lalta OEL - TWA	5 ppm
	8 mg/m ³
letherlands OEL - TWA	8 mg/m ³
oland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 ppm
	8 mg/m ³
Romania OEL - TWA	5 ppm
	8 mg/m ³
lovakia OEL - TWA	5 ppm
	8.0 mg/m ³
Blovenia OEL - TWA	5 ppm
	8 mg/m ³
pain OEL - TWA	5 ppm
	7.6 mg/m ³
witzerland OEL -TWAs	-
WILZGHANG ULL - I WAS	2 ppm 3.0 mg/m ³
/ietnam OEL - TWAs	5 mg/m ³
	o mg/m
M CHLORIDE	
	5 mg/m ³
atvia OEL - TWA	5 mg/m ³
ithuania OEL - TWA	5 mg/m ³
	o (3)
CGIH Ceiling Threshold Limit:	2 mg/m ³
ustralia PEAK	2 mg/m ³
ustria OEL - MAKs	2 mg/m ³
AUSINA OEL - WARS	
Bulgaria OEL - TWA	2.0 mg/m ³

Material Name: Ropivacaine Hydrochloride Solution for Injection Revision date: 15-Aug-2016 Page 5 of 10

Version: 2.2

8. EXPOSURE CONTROLS / F			
Estonia OEL - TWA		mg/m ³	
France OEL - TWA		2 mg/m ³	
Greece OEL - TWA	2 mg/m ³		
Hungary OEL - TWA		mg/m ³	
Japan - OELs - Ceilings		mg/m ³	
Latvia OEL - TWA		0.5 mg/m ³	
OSHA - Final PELS - TWAs:		mg/m ³	
Poland OEL - TWA		0.5 mg/m ³	
Slovakia OEL - TWA		mg/m ³	
Slovenia OEL - TWA		mg/m ³	
Sweden OEL - TWAs		mg/m ³	
Switzerland OEL -TWAs	2	2 mg/m ³	
The purpose of the Occupational Expo when the available data are sufficient t based upon an analysis of all currently available.	o do so, but inadequate to esta	ablish an Occupational Exposure Lin	nit (OEL). The OEB given is
Ropivacaine hydrochloride Pfizer Occupational Exposure Band (OEB):	• OEB 3 (control exposure to	the range of 10ug/m ³ to < 100ug/m ³))
Exposure Controls Engineering Controls:		be used as the primary means to co ventilation, or other engineering cont	
Personal Protective Equipment:	protective equipment (PPE) supplier for assistance in se	standards and regulations in the sel Contact your safety and health pro lecting the correct protective clothing e conditions, other chemicals used o es.	fessional or safety equipment g/equipment based on an
Hands:	possible and for bulk proces	le, etc.) are recommended if skin co sing operations. (Protective gloves	must meet the standards in
Eyes:	accordance with EN374, ASTM F1001 or international equivalent.) Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)		
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)		
Respiratory protection:	exceeded, wear an appropri to below the OEB (e.g. parti	use, if the applicable Occupational E ate respirator with a protection facto culate respirator with a half mask, P dance with EN140, EN143, ASTM F	r sufficient to control exposures 3 filter). (Respirators must
9. PHYSICAL AND CHEMICAL	PROPERTIES		
Physical State:	Solution	Color:	No data available.
Odor:	No data available.	Odor Threshold:	No data available.

Molecular Weight:

328.88

C16H25CIN2O

No data available

Solvent Solubility:

Molecular Formula:

PZ02415

Material Name: Ropivacaine Hydrochloride Solution for Injection Revision date: 15-Aug-2016

9. PHYSICAL AND CHEMICAL PROPERTIES

Water Solubility: Soluble No data available. No data available No data available. Log P 2.15 No data available. No data available Autoignition Temperature (Solid) (°C): Flammability (Solids):

Flash Point (Liquid) (°C): Upper Explosive Limits (Liquid) (% by Vol.): Lower Explosive Limits (Liquid) (% by Vol.):

10. STABILITY AND REACTIVITY

Reactivity: No data available **Chemical Stability:** Stable at normal conditions **Possibility of Hazardous Reactions Oxidizing Properties:** No data available **Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers No data available **Hazardous Decomposition Products:**

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects Short Term: Known Clinical Effects:

Anesthetic drug: may cause central nervous system and cardiovascular system effects May cause tingling/itching (paresthesia), allergic reaction, decrease in blood pressure (hypotension), decreased heart rate (bradycardia), respiratory depression.

Acute Toxicity: (Species, Route, End Point, Dose)

Ropivacaine hydrochloride

LD50 9.9 mg/kg Rat IV

Page 6 of 10

Version: 2.2

No data available No data available No data available

No data available No data available

pH: Melting/Freezing Point (°C): Boiling Point (°C): Partition Coefficient: (Method, pH, Endpoint, Value) Ropivacaine hydrochloride No data available SODIUM CHLORIDE No data available HYDROCHLORIC ACID No data available SODIUM HYDROXIDE No data available Water for Injection No data available Decomposition Temperature (°C): **Evaporation Rate (Gram/s):** Vapor Pressure (kPa): Vapor Density (g/ml): **Relative Density:** Viscosity: Flammablity:

Material Name: Ropivacaine Hydrochloride Solution for Injection Revision date: 15-Aug-2016 Page 7 of 10

Version: 2.2

11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 980mg/kg Mouse Oral LD50 300mg/kg

SODIUM CHLORIDE

RatSub-tenon injection (eye)LC50/1hr> 42 g/m³RatOralLD 503g/kgMouseOralLD 504g/kgRabbitDermalLD 50> 10g/kg

HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Ropivacaine hydrochloride

2 Generation Reproductive Toxicity Rat No route specified Dose not specified Negative

HYDROCHLORIC ACID Bacterial Mutagenicity (Ames) Salmonella Negative In Vivo Micronucleus Rat Negative

<u>Carcinogen Status:</u> None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

HYDROCHLORIC ACID IARC:

Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

```
Environmental Overview: Releases to the environment should be avoided. Environmental properties have not been thoroughly investigated.
```

Toxicity: Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Ropivacaine hydrochlorideGreen algaeEC5072 Hours 59 mg/LDaphnia magna (Water Flea)EC5048 Hours 34 mg/LBrachydanio rerio (Zebra fish)LC5096 Hours 38 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: Partition Coefficient: (Method, pH, Endpoint, Value)

Material Name: Ropivacaine Hydrochloride Solution for Injection Revision date: 15-Aug-2016 Page 8 of 10

Version: 2.2

Ropivacaine hydrochloride

No data available Log P 2.15

Mobility in Soil:

No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Water for Injection	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the	Present
obligations of Register:	
EU EINECS/ELINCS List	231-791-2
HYDROCHLORIC ACID	
CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances	5000 lb
and their Reportable Quantities:	2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous	500 lb
TPQs	

Material Name: Ropivacaine Hydrochloride Solution for Injection Revision date: 15-Aug-2016

15. REGULATORY INFORMATION	
CERCLA/SARA - Section 302 Extremely Hazardous	5000 lb
Substances EPCRA RQs	
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 5
for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	231-595-7
SODIUM CHLORIDE	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-598-3
SODIUM HYDROXIDE	
CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances	1000 lb
and their Reportable Quantities:	454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 5
for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	215-185-5
Ropivacaine hydrochloride	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed Hazardous to the aquatic environment, acute toxicity-Cat.3; H402 - Harmful to aquatic life Hazardous to the aquatic environment, chronic toxicity-Cat.3; H412 - Harmful to aquatic life with long lasting effects Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources:	Publicly available toxicity information.
Reasons for Revision:	Updated Section 11 - Toxicology Information.
Revision date:	15-Aug-2016 Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Version: 2.2

Material Name: Ropivacaine Hydrochloride Solution for Injection Revision date: 15-Aug-2016 Page 10 of 10

Version: 2.2

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet